

16 October 2025

ASX Announcement

Firebrick Secures Investment from Philippines Partner

- **Additional investment received from Philippines strategic partner**
- **Placement price is \$0.085 per Share**

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that it has secured an additional investment from its existing strategic investor, Pharma Nutria N.A., Inc. (**PNAI**), which is an entity affiliated with the Company's licensing partner in the Philippines, SV More Pharma Corporation.

The investment value was \$102,000 by way of placement of 1.2 million shares at a price per share of 8.5 cents (\$0.085), representing a 31% premium over the closing price of FRE shares on 15 October 2025 of \$0.065. The 1.2 million shares will be issued pursuant to the Company's existing placement capacity under ASX Listing Rule 7.1. The Shares to be issued represent approximately 0.5% of current shares on issue (250,371,369).

The previous investment by PNAI was for \$1.1 million (announcement 4 March 2025). The current investment was requested by PNAI to restore its holding to above 5%, following the Company's recent placement of \$1.4 million to other investors (announcement 26 August 2025). The placement was agreed to by the Company on the basis that PNAI was unable to effectively trade on the market to otherwise increase their holding.

Director of PNAI, Mr Paul Santillana said:

"Pharma Nutria N.A., Inc. is proud to further strengthen its partnership with Firebrick Pharma through this additional investment. Our continued support reflects our confidence in Firebrick's vision, leadership, and in the long-term potential of Nasodine and its broader pipeline. As the exclusive partner for Nasodine in the Philippines, we are fully aligned with Firebrick's mission and committed to contributing to its success in the Philippine market. We look forward to the journey ahead and the opportunity to bring innovative healthcare solutions to more Filipino patients."

"This additional investment by PNAI to maintain its substantial shareholding is a positive signal and welcomed by the Firebrick board," said Dr Peter Molloy, Executive Chairman of Firebrick. "We are grateful for SV More Pharma Group's ongoing support and look forward to the approval of Nasodine Nasal Spray in the Philippines next year."

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with a launch in the Philippines expected in 2026.

Media enquiries:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au**Investor enquiries:**Investors@firebrickpharma.com